Published in Adv Pharmacol on January 01, 2008
Evolving spectrum and incidence of non-AIDS-defining malignancies. Curr Opin HIV AIDS (2009) 0.99
Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma. Clin Cancer Res (2012) 0.96
The viral interferon regulatory factors of KSHV: immunosuppressors or oncogenes? Front Immunol (2011) 0.94
Epithelial maturation and molecular biology of oral HPV. Infect Agent Cancer (2009) 0.86
Kaposi's sarcoma-associated herpesvirus and innate immunity. Future Virol (2010) 0.85
Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 1: human papillomavirus-mediated carcinogenesis. Head Face Med (2010) 0.81
A comparative analysis of clinical and molecular factors with the stage of cervical cancer in a Brazilian cohort. PLoS One (2013) 0.79
Human immunodeficiency virus-associated lung malignancies. Clin Chest Med (2013) 0.78
Identification of Kaposi Sarcoma Herpesvirus (KSHV) vIRF1 Protein as a Novel Interaction Partner of Human Deubiquitinase USP7. J Biol Chem (2016) 0.76
Kaposi sarcoma-associated herpesvirus serum DNA and antibodies not associated with subsequent non-Hodgkin lymphoma risk. J Acquir Immune Defic Syndr (2011) 0.75
Risk factors for common cancers among patients at Kamuzu Central Hospital in Lilongwe, Malawi: A retrospective cohort study. Malawi Med J (2017) 0.75
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (1994) 39.60
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med (1995) 21.16
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood (1995) 16.81
A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A (1983) 14.73
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A (1996) 12.89
Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature (1985) 11.11
Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet (1995) 10.63
An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell (1985) 10.13
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol (1989) 8.68
Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell (1991) 7.40
Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer (2004) 6.99
Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst (2005) 6.69
Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science (1996) 6.57
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature (1997) 6.23
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol (1990) 6.23
Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am J Pathol (1985) 6.18
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med (1996) 5.96
Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A (1993) 5.92
Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science (1999) 5.55
The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev (1999) 5.49
Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst (2000) 5.32
Spectrum of AIDS-associated malignant disorders. Lancet (1998) 5.30
Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae. J Virol (1996) 5.05
p53 inhibition by the LANA protein of KSHV protects against cell death. Nature (2000) 4.74
Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis (2006) 4.67
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33
A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus. J Virol (1998) 4.23
Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood (1996) 4.22
The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med (2000) 4.20
Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med (1996) 4.13
Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature (1997) 4.12
Epidemiology of genital human papillomavirus infection. Am J Med (1997) 4.09
Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J (1991) 4.07
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet (1996) 4.05
Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst (2000) 3.77
Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science (1997) 3.70
Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Morb Mortal Wkly Rep (1987) 3.66
Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J Virol (1986) 3.65
The action of oncogenes in the cytoplasm and nucleus. Science (1985) 3.62
Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol (1995) 3.57
Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet (1996) 3.54
Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma. J Virol (1996) 3.48
Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat Med (1997) 3.44
Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell (2003) 3.42
Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res (1989) 3.35
Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol (1996) 3.22
Determinants of genital human papillomavirus detection in a US population. J Infect Dis (2001) 3.21
AIDS-associated non-Hodgkin lymphoma. Lancet (1991) 3.20
The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene (1999) 3.17
A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat Med (2003) 3.10
The family Herpesviridae: an update. The Herpesvirus Study Group of the International Committee on Taxonomy of Viruses. Arch Virol (1992) 3.09
The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene (1995) 3.07
Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist (2003) 3.04
Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med (1997) 3.03
Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8. J Virol (1999) 3.02
Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J (1998) 3.01
A common function for polyoma virus large-T and papillomavirus E1 proteins? Nature (1984) 2.96
Stimulation of NF-kappa B-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J Virol (1995) 2.91
Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol (2006) 2.91
Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev (2003) 2.90
The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci U S A (1997) 2.90
Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J (1997) 2.87
Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst (2003) 2.81
Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature (1998) 2.76
Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature (1990) 2.72
The lytic switch protein of KSHV activates gene expression via functional interaction with RBP-Jkappa (CSL), the target of the Notch signaling pathway. Genes Dev (2002) 2.59
Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma. AIDS (1996) 2.49
NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A (2000) 2.48
Kaposi's sarcoma in recipients of renal transplants. Am J Med (1979) 2.45
The structure and coding organization of the genomic termini of Kaposi's sarcoma-associated herpesvirus. Virology (1997) 2.44
Human herpesvirus 8 infection within families in rural Tanzania. J Infect Dis (2003) 2.42
Papillomavirus sequences integrate near cellular oncogenes in some cervical carcinomas. Proc Natl Acad Sci U S A (1987) 2.40
Human papillomavirus (HPV) in head and neck cancer. J Clin Virol (2005) 2.40
KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med (2004) 2.39
Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus. Nat Med (1998) 2.38
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood (2001) 2.37
Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer (2004) 2.33
Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer (1996) 2.30
Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet (2000) 2.29
Update on acquired immune deficiency syndrome (AIDS)--United States. MMWR Morb Mortal Wkly Rep (1982) 2.25
Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature (1990) 2.23
Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene (1998) 2.22
Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J Exp Med (2000) 2.21
Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci U S A (1996) 2.18
The epidemiology of conjunctival squamous cell carcinoma in Uganda. Br J Cancer (2002) 2.18
Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells. J Virol (2000) 2.17
A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus. J Virol (1999) 2.16
Opportunistic infections and Kaposi's sarcoma in homosexual men. N Engl J Med (1981) 2.09
Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J (1999) 2.09
Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation. J Virol (1997) 2.05
Isolation and characterization of various complexes of the minichromosome maintenance proteins of Schizosaccharomyces pombe. J Biol Chem (2000) 2.04
Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J Virol (1996) 2.03
Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene. J Virol (1998) 2.02
The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol (1995) 2.02
Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol (1998) 2.02
Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice. J Virol (2006) 2.24
Postnatal human herpesvirus 8 and human immunodeficiency virus type 1 infection in mothers and infants from Zambia. J Infect Dis (2003) 1.74
Human immunodeficiency virus type 1 (HIV-1) tat induces nitric-oxide synthase in human astroglia. J Biol Chem (2002) 1.73
Traditional practices and exposure to bodily fluids in Lusaka, Zambia. Trop Med Int Health (2007) 1.71
The role of Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 regulator of transcription activation (RTA) in control of gene expression. Oncogene (2003) 1.56
The distribution of sexually-transmitted Human Papillomaviruses in HIV positive and negative patients in Zambia, Africa. BMC Infect Dis (2007) 1.36
Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J Biol Chem (2002) 1.28
Modulation of human herpesvirus 8/Kaposi's sarcoma-associated herpesvirus replication and transcription activator transactivation by interferon regulatory factor 7. J Virol (2005) 1.19
Epidemiological characteristics of human herpesvirus-8 infection in a large population of antenatal women in Zambia. J Med Virol (2005) 1.19
Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease. Retrovirology (2006) 1.19
Distribution of Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 in maternal saliva and breast milk in Zambia: implications for transmission. J Infect Dis (2004) 1.15
Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection. J Virol (2008) 1.14
Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission. Virology (2010) 1.13
Infectious molecular clone of a recently transmitted pediatric human immunodeficiency virus clade C isolate from Africa: evidence of intraclade recombination. J Virol (2004) 1.13
HIV-1 effects on neuropsychological performance in a resource-limited country, Zambia. AIDS Behav (2011) 1.12
Early childhood infection by human herpesvirus 8 in Zambia and the role of human immunodeficiency virus type 1 coinfection in a highly endemic area. Am J Epidemiol (2008) 1.11
Enhancement of autophagy during lytic replication by the Kaposi's sarcoma-associated herpesvirus replication and transcription activator. J Virol (2010) 1.09
Clade C HIV-1 isolates circulating in Southern Africa exhibit a greater frequency of dicysteine motif-containing Tat variants than those in Southeast Asia and cause increased neurovirulence. Retrovirology (2013) 1.09
Interferon regulatory factor 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes. J Virol (2008) 1.09
Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant. Retrovirology (2005) 1.07
Compartmentalization of HIV-1 in the central nervous system: role of the choroid plexus. AIDS (2005) 1.06
Phylogenetic and phenotypic analysis of HIV type 1 env gp120 in cases of subtype C mother-to-child transmission. AIDS Res Hum Retroviruses (2002) 1.06
NeuroAIDS in Africa. J Neurovirol (2010) 1.05
Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. Blood (2002) 1.05
Type I interferons and interferon regulatory factors regulate TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected macrophages. PLoS One (2009) 1.04
Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas. J Virol (2007) 1.04
Development of an immunofluorescence assay using recombinant proteins expressed in insect cells to screen and confirm presence of human herpesvirus 8-specific antibodies. Clin Vaccine Immunol (2008) 1.03
Kaposi's sarcoma-associated herpesvirus transactivator RTA promotes degradation of the repressors to regulate viral lytic replication. J Virol (2008) 1.03
The human immunodeficiency virus type 1 envelope confers higher rates of replicative fitness to perinatally transmitted viruses than to nontransmitted viruses. J Virol (2008) 1.02
Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 replication and transcription activator regulates viral and cellular genes via interferon-stimulated response elements. J Virol (2005) 1.02
The transcriptional repressor K-RBP modulates RTA-mediated transactivation and lytic replication of Kaposi's sarcoma-associated herpesvirus. J Virol (2007) 1.01
Kaposi sarcoma-associated herpesvirus degrades cellular Toll-interleukin-1 receptor domain-containing adaptor-inducing beta-interferon (TRIF). J Biol Chem (2011) 1.01
The latent membrane protein 1 of Epstein-Barr virus establishes an antiviral state via induction of interferon-stimulated genes. J Biol Chem (2004) 1.00
Humanized-BLT mouse model of Kaposi's sarcoma-associated herpesvirus infection. Proc Natl Acad Sci U S A (2014) 1.00
The latent membrane protein 1 of Epstein-Barr virus (EBV) primes EBV latency cells for type I interferon production. J Biol Chem (2006) 0.99
HIV-1 clade B and C isolates exhibit differential replication: relevance to macrophage-mediated neurotoxicity. Neurotox Res (2011) 0.98
Restricted genetic diversity of HIV-1 subtype C envelope glycoprotein from perinatally infected Zambian infants. PLoS One (2010) 0.96
Positron emission tomography-computed tomography surveillance for the node-positive neck after chemoradiotherapy. Laryngoscope (2009) 0.94
Genetic variation in mother-child acute seroconverter pairs from Zambia. AIDS (2008) 0.92
Global NeuroAIDS roundtable. J Neurovirol (2013) 0.92
Human Ubc9 contributes to production of fully infectious human immunodeficiency virus type 1 virions. J Virol (2009) 0.90
Subtype-associated differences in HIV-1 reverse transcription affect the viral replication. Retrovirology (2010) 0.89
The zinc finger DNA-binding domain of K-RBP plays an important role in regulating Kaposi's sarcoma-associated herpesvirus RTA-mediated gene expression. Virology (2009) 0.89
Human herpesvirus 8 seroprevalence, China. Emerg Infect Dis (2012) 0.89
The normal increase in adrenal secretion during pregnancy contributes to maternal volume expansion and fetal homeostasis. J Soc Gynecol Investig (2002) 0.88
Lysine residues of interferon regulatory factor 7 affect the replication and transcription activator-mediated lytic replication of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. J Gen Virol (2010) 0.88
Chronology and evolution of the HIV-1 subtype C epidemic in Ethiopia. AIDS (2010) 0.87
Primary gamma-herpesviral infection in Zambian children. BMC Infect Dis (2010) 0.87
Molecular determinants of HIV-1 subtype C coreceptor transition from R5 to R5X4. Virology (2010) 0.86
GenomeBlast: a web tool for small genome comparison. BMC Bioinformatics (2006) 0.86
Short communication: antiretroviral therapy resistance mutations present in the HIV type 1 subtype C pol and env regions from therapy-naive patients in Zambia. AIDS Res Hum Retroviruses (2010) 0.85
Kaposi's sarcoma at the University Teaching Hospital, Lusaka, Zambia in the antiretroviral therapy era. Int J Cancer (2014) 0.84
A twin-cysteine motif in the V2 region of gp120 is associated with SIV envelope trimer stabilization. PLoS One (2013) 0.83
Identification and characterization of a new Kaposi's sarcoma-associated herpesvirus replication and transcription activator (RTA)-responsive element involved in RTA-mediated transactivation. J Gen Virol (2009) 0.83
Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma. PLoS One (2008) 0.83
Risk factors for early childhood infection of human herpesvirus-8 in Zambian children: the role of early childhood feeding practices. Cancer Epidemiol Biomarkers Prev (2013) 0.82
The Zambia Children's KS-HHV8 Study: rationale, study design, and study methods. Am J Epidemiol (2011) 0.82
A comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression. AIDS (2009) 0.82
CRF07_BC Strain Dominates the HIV-1 Epidemic in Injection Drug Users in Liangshan Prefecture of Sichuan, China. AIDS Res Hum Retroviruses (2015) 0.82
Pathogenicity and rapid growth kinetics of feline immunodeficiency virus are linked to 3' elements. PLoS One (2011) 0.81
Early Initiation of Antiretroviral Therapy Can Functionally Control Productive HIV-1 Infection in Humanized-BLT Mice. J Acquir Immune Defic Syndr (2015) 0.81
Localization of human herpesvirus type 8 in human sperms by in situ PCR. J Mol Histol (2006) 0.81
Early childhood infection of Kaposi's sarcoma-associated herpesvirus in Zambian households: a molecular analysis. Int J Cancer (2012) 0.80
Kaposi's sarcoma-associated herpesvirus transactivator Rta induces cell cycle arrest in G0/G1 phase by stabilizing and promoting nuclear localization of p27kip. J Virol (2013) 0.80
Toll-like receptor 7 stimulates the expression of Epstein-Barr virus latent membrane protein 1. PLoS One (2012) 0.80
Higher levels of neutralizing antibodies against KSHV in KS patients compared to asymptomatic individuals from Zambia. PLoS One (2013) 0.79
Dynamics of envelope evolution in clade C SHIV-infected pig-tailed macaques during disease progression analyzed by ultra-deep pyrosequencing. PLoS One (2012) 0.79
Kaposi`s sarcoma associated herpesvirus infection among female sex workers and general population women in Shanghai, China: a cross-sectional study. BMC Infect Dis (2014) 0.79
TLR-TRIF pathway enhances the expression of KSHV replication and transcription activator. J Biol Chem (2013) 0.78
Differences in platelet indices between healthy Han population and Tibetans in China. PLoS One (2013) 0.78
Interferon regulatory factor 4 (IRF-4) targets IRF-5 to regulate Epstein-Barr virus transformation. J Biol Chem (2011) 0.78
CD20 antibody primes B lymphocytes for type I interferon production. PLoS One (2013) 0.78
The interaction between KSHV RTA and cellular RBP-Jkappa and their subsequent DNA binding are not sufficient for activation of RBP-Jkappa. Virus Res (2007) 0.78
Unique epitope of bovine immunodeficiency virus gag protein spans the cleavage site between p16(MA) and p2L. Clin Diagn Lab Immunol (2002) 0.78
Construction and characterization of a chimeric virus (BIV/HIV-1) carrying the bovine immunodeficiency virus gag-pol gene. AIDS (2002) 0.78
Human Ubc9 is involved in intracellular HIV-1 Env stability after trafficking out of the trans-Golgi network in a Gag dependent manner. PLoS One (2013) 0.77
Dual functions of interferon regulatory factors 7C in Epstein-Barr virus-mediated transformation of human B lymphocytes. PLoS One (2010) 0.77
Comparative analysis of the fusion efficiency elicited by the envelope glycoprotein V1-V5 regions derived from human immunodeficiency virus type 1 transmitted perinatally. J Gen Virol (2012) 0.77
Cellular tropisms and co-receptor usage of HIV-1 isolates from vertically infected children with neurological abnormalities and rapid disease progression. J Med Virol (2002) 0.76
Human papillomavirus 16 variants from Zambian women with normal pap smears. J Med Virol (2011) 0.76
Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy. J Med Virol (2005) 0.76
Use of average mutual information for studying changes in HIV populations. Conf Proc IEEE Eng Med Biol Soc (2009) 0.76
Loss of the pregnancy-induced rise in cortisol concentrations in the ewe impairs the fetal insulin-like growth factor axis. Reprod Fertil Dev (2011) 0.76
Mortality among HIV-1- and human herpesvirus type 8-affected mother-infant pairs in Zambia. Cancer Epidemiol Biomarkers Prev (2008) 0.75
HIV-1 Env C2-V4 diversification in a slow-progressor infant reveals a flat but rugged fitness landscape. PLoS One (2013) 0.75
Re: Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst (2008) 0.75
Analysis of primary resistance mutations to HIV-1 entry inhibitors in therapy naive subtype C HIV-1 infected mother-infant pairs from Zambia. J Clin Virol (2013) 0.75
Clinical application of positron emission tomography in designing radiation fields in non-small cell lung cancer patients. Exp Ther Med (2010) 0.75
Viral transformation for production of personalized type I interferons. Biotechnol J (2010) 0.75
Observed and expected incidence of cervical cancer in lusaka and the southern and Western provinces of Zambia, 2007 to 2012. Int J Gynecol Cancer (2015) 0.75
Variations in the Biological Functions of HIV-1 Clade C Envelope in a SHIV-Infected Rhesus Macaque during Disease Progression. PLoS One (2013) 0.75
HIV drug resistance in infants increases with changing prevention of mother-to-child transmission regimens. AIDS (2017) 0.75
Challenges and counter challenges in HIV/AIDS. Chin Med J (Engl) (2010) 0.75
Directed self-assembly in laponite/CdSe/polyaniline nanocomposites. Langmuir (2008) 0.75
HIV drug resistance in infants increases with changing PMTCT regimens. AIDS (2017) 0.75